Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Will, B; Siddiqi, T; Alberich Jordà, M; Shimamura, T; Luptakova, K; Staber, PB; Costa, DB; Steidl, U; Tenen, DG; Kobayashi, S.
Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.
Blood. 2010; 115(14):2901-2909 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Autor/innen der Med Uni Graz:
Staber Philipp Bernhard

Dimensions Citations:

Plum Analytics:
Number of Figures: 6
| | | | | |
The activating mutation JAK2 V617F plays a central role in the pathogenesis of polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Inhibition of JAK2 activity leads to growth inhibition and apoptosis in cells with mutated JAK2. However, the proapoptotic proteins involved in JAK2 inhibition-induced apoptosis remain unclear. In this study, we show that JAK2 inhibition-induced apoptosis correlated with up-regulation of the nonphosphorylated form of the BH3-only protein Bim in hematopoietic cell lines bearing JAK2 mutations. Knockdown of Bim dramatically inhibited apoptosis induced by JAK2 inhibition, which was reversed by the BH3 mimetic agent ABT-737. In addition, ABT-737 enhanced the apoptosis induced by JAK2 inhibition in JAK2 V617F(+) HEL and SET-2 cells. The combination of JAK inhibitor I and ABT-737 reduced the number of erythroid colonies derived from CD34(+) cells isolated from JAK2 V617F(+) polycythemia vera patients more efficiently than either drug alone. These data suggest that Bim is a key effector molecule in JAK2 inhibition-induced apoptosis and that targeting this apoptotic pathway could be a novel therapeutic strategy for patients with activating JAK2 mutations.
Find related publications in this database (using NLM MeSH Indexing)
Apoptosis - drug effects Apoptosis - genetics
Apoptosis Regulatory Proteins - genetics Apoptosis Regulatory Proteins - metabolism
Biomimetic Materials - pharmacology
Biphenyl Compounds - pharmacology
Erythroid Cells - metabolism
Female -
Humans -
Janus Kinase 2 - antagonists and inhibitors Janus Kinase 2 - genetics Janus Kinase 2 - pharmacology
K562 Cells -
Male -
Membrane Proteins - genetics Membrane Proteins - metabolism
Mutation -
Nitrophenols - pharmacology
Piperazines - pharmacology
Polycythemia Vera - drug therapy Polycythemia Vera - genetics Polycythemia Vera - metabolism
Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins - metabolism
Sulfonamides - pharmacology

© Meduni Graz Impressum